Nova IVI

Sector: Pharma & Healthcare (IVF / Fertility Clinic)  |  HQ: India  |  Founded: Not separately disclosed  |  Employees: Not separately disclosed

Listed as: Privately held  | 

Company overview

Nova IVI operates in the pharma & healthcare segment of the Indian market, with a presence noted in the ivf / fertility clinic category. The company is among the recognised participants in this segment alongside other Indian and multinational players. Operations follow the standard Companies Act 2013 disclosure framework where Nova IVI is incorporated as a private or public limited company under Indian law, with statutory audit, GST registration under the CGST Act 2017, and applicable sectoral compliance under FSSAI, BIS, MoEF, or sectoral regulators as relevant to the activity. The competitive set in ivf / fertility clinic includes pan-India brands, regional players, and multinational subsidiaries operating in India through wholly-owned or joint-venture structures.

Recent developments

2012 - 2019

Nova IVI Fertility underwent a significant ownership change in May 2019 when TPG-backed Asia Healthcare Holdings (AHH) acquired the company for approximately $100 million [1][2][5][8]. Following this transaction, the organization rebranded to Nova IVF Fertility in December 2019 [7], marking a new chapter under the AHH umbrella.

Prior to the acquisition, Nova IVI Fertility had pursued an aggressive expansion strategy, including a 2012 joint venture with IVI Spain involving a Rs 250 crore investment commitment [10] and the opening of its eleventh center in Pune by early 2016 [9]. The company garnered industry recognition during this period, with Medical Director Dr. Manish Banker receiving the prestigious Dr. B.C. Roy National Award in 2018 [6] and the clinic being named the Medical Value Travel IVF Specialist Hospital in 2017 [3]. Industry data from November 2018 indicated the Indian fertility sector was expanding at 15-20% annually, underscoring the market opportunity that Nova had targeted [4].

Sources (9)

1. Asia Healthcare Holdings (AHH) acquires Nova IVI Fertility - TPG Inc. · TPG Inc. · Thu, 02 May 2019
2. Asia Healthcare Holdings acquires Nova IVI Fertility - BioSpectrum India · BioSpectrum India · Fri, 03 May 2019
3. Nova IVI Fertility Receives the Medical Value Travel IVF Specialist Hospital Award - Medical Dialogues · Medical Dialogues · Fri, 20 Oct 2017
4. Indian fertility industry has been growing by 15-20% YoY, said Dr Manish Banker, Nova IVI Fertility - ET HealthWorld · ET HealthWorld · Wed, 28 Nov 2018
5. TPG-backed AHH buys Nova IVI Fertility for $100 mn - The Economic Times · The Economic Times · Thu, 02 May 2019
6. Dr. Manish Banker, Medical Director of Nova IVI Fertility, is Selected for the Prestigious Dr. B. C. Roy National Award - PR Newswire · PR Newswire · Tue, 04 Sep 2018
7. ‘Nova IVI Fertility’ is now ‘Nova IVF Fertility’ - Mediabrief.com · Mediabrief.com · Tue, 17 Dec 2019
8. TPG's Asia Healthcare Holdings acquires Nova IVI Fertility chain for undisclosed amount - Moneycontrol.com · Moneycontrol.com · Thu, 02 May 2019
9. Nova Pulse IVF forms JV with IVI Spain; to invest Rs 250 crore - The Economic Times · The Economic Times · Wed, 11 Apr 2012

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

Nova IVI occupies a position in the ivf / fertility clinic category alongside other listed and unlisted Indian players. Competitive intensity in the segment is shaped by raw material cost cycles, distribution depth, branded versus unbranded share, and the regulatory framework governing manufacturing, FSSAI labelling (for food), BIS standards (for engineering goods), or sectoral norms. The principal competitive moats in this category are typically scale, distribution reach, brand trust, and integrated procurement. KAMRIT's project report on ivf / fertility clinic benchmarks new entrant economics against the listed peer cost structure including capex per tonne (or per unit of output), working capital intensity, gross margin band, and the EBITDA delta between organised and unorganised participants.

Key risks

Input cost volatility in the ivf / fertility clinic value chain Competitive intensity from larger Indian groups and multinational subsidiaries Regulatory tightening under FSSAI, BIS, environmental norms, or labour codes

Outlook

Nova IVI is a participant in the Indian ivf / fertility clinic category, which forms part of the broader Pharma & Healthcare space. The Indian ivf / fertility clinic market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For Nova IVI specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for Nova IVI mirrors the broader ivf / fertility clinic category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for Nova IVI as a peer benchmark within the ivf / fertility clinic category. For investors, lenders, or new entrant promoters seeking a fuller assessment of Nova IVI, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with Nova?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharma & healthcare (ivf / fertility clinic) sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Nova and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Nova IVI in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.